NUTX vs ADUS

For growth investors, Nutex Health, Inc.

(NUTX) is the stronger pick with 82. 4% revenue growth year-over-year, versus 23. 2% for Addus HomeCare Corporation (ADUS). Nutex Health, Inc. (NUTX) offers the better valuation at 12. 5x trailing P/E (8. 5x forward), making it the more compelling value choice. Analysts rate Nutex Health, Inc. (NUTX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Nutex Health, Inc.

(NUTX) is the cheapest at 12. 5x versus Addus HomeCare Corporation at 18. 5x. On forward P/E, Nutex Health, Inc. is actually cheaper at 8. 5x.

Over the past 5 years, Addus HomeCare Corporation (ADUS) delivered a total return of +2.

6%, compared to -97. 8% for Nutex Health, Inc. (NUTX). Over 10 years, the gap is even starker: ADUS returned +427. 2% versus NUTX's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Addus HomeCare Corporation (ADUS) is the lower-risk stock at 0.

58β versus Nutex Health, Inc. 's 2. 01β — meaning NUTX is approximately 250% more volatile than ADUS relative to the S&P 500. On balance sheet safety, Addus HomeCare Corporation (ADUS) carries a lower debt/equity ratio of 19% versus 83% for Nutex Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nutex Health, Inc.

(NUTX) is pulling ahead at 82. 4% versus 23. 2% for Addus HomeCare Corporation (ADUS). On earnings-per-share growth, the picture is similar: Addus HomeCare Corporation grew EPS 23. 2% year-over-year, compared to 7. 9% for Nutex Health, Inc.. Over a 3-year CAGR, NUTX leads at 58. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nutex Health, Inc.

(NUTX) is the more profitable company, earning 8. 1% net margin versus 6. 7% for Addus HomeCare Corporation — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NUTX leads at 31. 5% versus 9. 7% for ADUS. At the gross margin level — before operating expenses — NUTX leads at 50. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Nutex Health, Inc.

(NUTX) trades at 8. 5x forward P/E versus 14. 0x for Addus HomeCare Corporation — 5. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUTX: 57. 0% to $205. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Addus HomeCare Corporation (ADUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

58), +427. 2% 10Y return). Nutex Health, Inc. (NUTX) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ADUS: +427. 2%, NUTX: -97. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.